Company Snapshot

Investment Thesis

Regeneron’s monoclonal antibody platform underpins Eylea, Dupixent (with Sanofi), and a deep immunology/oncology pipeline. Increasing Dupixent penetration and next-gen eye therapies sustain growth.

  • Dupixent Momentum: Expanding into COPD and pediatric indications drives multi-billion growth.
  • Ophthalmology Leadership: High-dose aflibercept and gene therapies defend retina franchise.
  • Pipeline Breadth: Bispecific antibodies, LNP delivery, and genetic medicines diversify revenue.

Strategic Mix

Immunology Dupixent, Kevzara, and inflammatory pipeline assets
Ophthalmology Eylea HD, gene therapy candidates, and device innovation
Oncology & Rare Diseases Libtayo, bispecifics, and metabolic programs
Collaborations Sanofi and Bayer co-development/royalty agreements

Mix reflects Regeneron’s therapeutic area disclosures.

Recent Performance

MTD -2.80%
QTD +5.60%
YTD -11.41%
5Y +7.91%

Shares have been volatile amid payor dynamics, yet Regeneron's durable cash flow and innovative pipeline keep long-term growth intact.

Strategic Insights

Manufacturing Scale

In-house biologics capacity supports rapid supply ramp.

AI/Genetics

Regeneron Genetics Center informs target discovery and patient selection.

Label Expansion

Broader Dupixent/COPD and Eylea HD indications extend cash flows.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...